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Cyclin E levels are high during late G1 and early S-phase in normal cells. The cyclin E expression over the cell cycle in tumours is not
fully known. The impact on patient outcome by high cyclin E levels during other parts of the cell cycle than late G1- and early S-phase
is unknown. We set out to study the expression of cyclin E over the cell cycle in cervical carcinomas. Using immunofluorescence
staining of cyclin A, digital microscopy, and digital image analysis, we determined which cells in a tissue section that were in S- or G2-
phase. M-phase cells were detected by morphology. By simultaneously staining for cyclin E, we investigated the variation in cyclin E
levels over the cell cycle in cervical carcinoma lesions. In a case–control study, in which each deceased patient was matched with a
patient still alive and well after 45 years of follow-up, we found that the deceased patients had a considerably higher fraction of cyclin
A-positive cells staining for cyclin E than the survivors (n¼36). We conclude that parallel cyclin E and cyclin A expression is an
indicator for poor outcome in cervical carcinomas. In addition, we investigated the expression pattern of cyclin E and cyclin A in
consecutive biopsy samples from cervical carcinomas at different stages, as well as in human papillomavirus positive or negative
adenocarcinomas in order to further study the cyclin E and cyclin A expression pattern in neoplastic lesions of the uterine cervix.
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Cervical carcinoma is the third most common malignant disease in
women worldwide. Approximately 370000 new cases are detected
annually (Parkin et al, 1999). Two main histological types of
cervical carcinomas exist, squamous cell carcinoma (SCC) and
adenocarcinoma (AC). Squamous cell carcinoma is more common
(80%) than AC (15%), and probably develops almost exclusively
under the influence of human papillomavirus (HPV) infection
(Bohmer et al, 2003), whereas 30% of the AC tumours lack HPV
involvement (Andersson et al, 2003). The incidence of SCC has
dropped in the last decades in the developed countries owing to
successful screening programmes. Approximately 40% of patients
diagnosed with cervical carcinoma in the developed countries die
from their disease. The main predictors for outcome include stage,
grade, and age at the time of diagnosis.
Cyclin E is a member of the cyclin protein family originally
discovered in 1983 (Evans et al, 1983). The primary characteristics
of the cyclins are their cell-cycle-specific expression patterns, and
their association with and subsequent activation of cyclin-
dependent kinases (CDKs). Cyclin E levels begin to rise in mid-
G1, peak during late G1, and drop off around the G1/S border
(Ekholm et al, 2001). Cyclin E associates with CDK2. The normal
cell progresses through G1 by passing through the G1 restriction
point in response to extracellular signals during early G1. Cyclin E
then accumulates leading to high cyclin E-dependent CDK2 kinase
activity. Cyclin A synthesis then ensues, which leads to S-phase
entry. In S-phase, cyclin E is quickly degraded, whereas the cyclin
A levels continue to increase throughout S and G2.
A link between overexpression of cyclin E and transformation
has been established in model systems (Keyomarsi and Pardee,
1993; Bortner and Rosenberg, 1997). The studies do, however, not
address whether it is the increased amount of cyclin E, the
presence of aberrant isoforms of cyclin E, or the heterochronic
expression (the expression of cyclin E during other phases of the
cell cycle than late G1 and early S-phase) of cyclin E that drives
transformation. There are also similarly unspecific studies on the
clinical implications of cyclin E overexpression (Porter et al, 1997;
Keyomarsi et al, 2002). The presence and clinical implications of
high cyclin E levels in tumour cells in late S-phase and/or G2-phase
have not been possible to study with the methodology used
previously.
Using immunofluorescence staining, digital microscopy, and
image analysis techniques, we set out to investigate the clinical
implications of the heterochronic cyclin E expression pattern
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soccurring in cervical carcinoma lesions. We have previously shown
that cyclin A staining above the minimal detectable level is a
dependable marker for cells in S- or G2-phase (Erlandsson et al,
2000). By parallel determination of the levels of cyclin E and cyclin
A in individual cells from cervical lesions, we were able to detect
the presence of abnormally high cyclin E levels in cells containing
cyclin A, that is, in cells likely to be in S- or G2-phase.
MATERIALS AND METHODS
Many of the experimental procedures used, such as the immuno-
fluorescence staining protocol, controls, and image acquisition,
have been previously described in detail (Erlandsson et al, 2003).
Selection and acquisition of tumour biopsies
Three different groups of patients were studied. The importance of
the cyclin E expression during S-phase for survival was studied in a
group of 36 patients treated for cervical carcinoma stage Ib or IIa
at the Department of Gynecological Oncology, Radiumhemmet,
Karolinska Hospital between 1994 and 1997. Of the patients, 18
died within 13 years after the date of diagnosis, and each of these
were matched with a survivor patient with respect to age, stage,
grade, lymph node status, and treatment, but which was
considered disease free after treatment and more than 5 years of
follow-up. We also tried to keep tumour size at diagnosis, smoking
habits, parity, and the prior usage of hormonal replacement
therapy as similar as possible between the deceased and the
survivors. The stage of transformation that cyclin E deregulation
occurs at was investigated using multiple biopsy samples from 13
patients treated at the Umea ˚ University Hospital between 1982 and
2000 for cervical lesions at different stages. Two or more biopsies
at different stages of the disease were available from each patient.
The cyclin E expression pattern in AC of the uterine cervix was
studied using tumour samples from 19 selected patients from a
larger previously described set of tumours (Andersson et al, 2001).
The study has been approved by Institutional Review Boards and
Ethical Committees from various participating hospitals.
Handling and staining of tissue sections
Routinely handled cervical biopsies acquired before treatment
were routinely fixed in formalin and embedded in paraffin.
Sections (4mm thick) were cut from each tumour, and attached to
glass slides. The first and last sections were subjected to
histopathological evaluation to confirm tumour status. The slides
were stored at  201C, and rehydrated through a ladder of graded
alcohols before staining. Antigenic recovery was performed
through microwave cooking for 3 5min in a 0.1 M citrate buffer
at pH 6.0. The slides were then washed in washing buffer (0.3mM
NaCl and 0.02% Tween 20 in a buffer consisting of 0.05mM Tris-
HCl at pH 7.6) for 10min, followed by incubation for 15min in
blocking buffer (1% bovine serum albumin and 0.5% Tween 20
dissolved in phosphate-buffered saline). Thereafter, they were
incubated with the primary antibodies diluted in blocking buffer
for 48h at room temperature (RT). Unbound and nonspecifically
bound antibodies were removed by washing in washing buffer for
3 20min. To block nonspecific binding of the secondary
antibodies, the slides were incubated with 4% donkey serum
diluted in blocking buffer for 30min. The secondary antibodies,
diluted in 4% donkey serum in blocking buffer, were added during
incubation for 30min at RT. The coverslips were then washed in
washing buffer for 3 20min. Finally, the coverslips were
mounted for fluorescence microscopy in H-1200 mounting
medium containing 2-(4-amidinophenyl)-6-indolecarbamidine di-
hydrochloride (DAPI) (Vector Laboratories Inc., Burlingame, CA,
USA).
The primary antibodies used were the cyclin E monoclonal
antibody HE12 and the cyclin A rabbit polyclonal antibody H-432
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The secondary
antibodies included a fluorescein isothiocyanate (FITC)-conju-
gated anti-rabbit antibody, and a cyanine 3-dUTP (Cy3)-con-
jugated anti-mouse antibody (Jackson ImmunoResearch Labs Inc.,
West Grove, PA, USA). Subsequently, the staining protocol
resulted in cell nuclei stained with DAPI, cyclin A stained with
FITC, and cyclin E stained with Cy-3. Only tumour samples
exhibiting a reliable staining result were used in the further
analysis.
Image acquisition and analysis
Images of approximately 1000–3000 cells from two to five discrete
areas from each slide were acquired using a Delta Vision system
(Applied Precision Inc., Issaqua, WA, USA) equipped with a
monochrome water-cooled CCD camera (Photometrics Ltd, Tuc-
son, AZ, USA). A Plan-Neofluar 63x/NA1.40 lense was used (Carl
Zeiss, Switzerland), resulting in images with a resolution of 0.2mm.
The built-in Delta Vision calibration system was applied, which
compensated for any nonlinearity in the CCD elements or any
consistently uneven light distribution in the microscope. Each
image acquisition involved taking three photos, with the optical
filter sets for detection of DAPI, FITC, and Cy-3, respectively.
Controls were used to exclude any possibility of antibody cross-
reactions or imperfections in the used optical filters. The tumour
areas with the highest percentage of cells staining for cyclin A
(i.e., with the highest proliferation) were preferentially imaged.
Image analysis was performed using the IMP image processing
software. Cell nuclei were manually segmented in the DAPI image.
The segmentation was then applied to the FITC and Cy3 images
and the amount of fluorescence emitted from each of the
fluorophores from each individual nucleus could then be
calculated. M-phase cells were identified based on the nuclear
morphology and investigated separately. Only staining arising
from cell nuclei was considered.
The intensity of the detected fluorescence signal is directly
proportional to the amount of fluorophore present in the specimen
(Schauenstein et al, 1978; Boddeke, 1999). Controls in which either
the monoclonal or polyclonal primary antibody was excluded
during the staining proved that there was no detectable crosstalk
between the FITC and Cy3 channels (data not shown). We
therefore conclude that the measured fluorescence can be assumed
to be linear to the levels of the stained antigen. As both cyclin E
and cyclin A staining is fairly homogeneously distributed
throughout the nucleus, the average fluorescence detected per
pixel can be assumed to represent a semiquantitative measurement
of the nuclear concentration of cyclin E and cyclin A. The
measured cyclin E and cyclin A levels can then be compared
between neighbouring cells, but not between cells from different
tumours.
In order to determine which cells stained positive for cyclin E
and/or cyclin A in each studied tumour area, we needed to set a
threshold level for each stain above which the measured
fluorescence would mark the cell as positive. An algorithm
previously described (Erlandsson et al, 2003) based on density
kernel estimates was used to automatically set objective thresholds
that separated the negative population of cell nuclei from those
actually containing cyclin E and/or cyclin A. In brief terms, the
algorithm creates a function that approximates the distribution of
the measurements as plotted in a histogram. Maxima in the second
derivative of the function are then calculated and proposed as
thresholds. However, in highly proliferative tumours, the negative
population was occasionally too small to be reliably detected by the
algorithm, and the thresholds were then manually set by visual
inspection of the original images, although aided by secondary
threshold suggestions by the algorithm.
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sRESULTS
A high fraction of S or G2 cells containing cyclin E is
associated with poor prognosis
The results of the clinical data of 36 patients (survivor/deceased)
with SCC are shown in Table 1. Half of the patients died within 3
years from the date of diagnosis, whereas the other half survived
and was considered disease free after more than 5 years of follow-
up without recurrence. The selected tumours were stained for
cyclin A and cyclin E and photographed. Using image analysis
methods described above, the nuclear content of the individual
cells was calculated. Cells staining above the threshold level for
cyclin A were considered to be cells in S- or G2-phase. The fraction
of these cells staining for cyclin E above the threshold level was
calculated for each tumour. The average is shown for each patient
in Table 1. In 15 out of 18 patient pairs, the deceased patient had a
higher fraction of cyclin A-positive cells staining for cyclin E than
the surviving patient did, which makes the difference in expression
patterns statistically significant (Po0.002). The results indicate
that a parallel expression of cyclin E and cyclin A is correlated to
poor outcome. Carcinomas of the uterine cervix containing cells
that simultaneously express cyclin E and cyclin A are more likely
to kill the host than the tumours that do not.
Figure 1 shows the cyclin A staining intensity plotted vs the
cyclin E staining intensity in three different tumours. It is evident
from the figure that these three tumours display highly different
cyclin E expression patterns. Calculating the fraction of cyclin A-
positive cells that stain positive for cyclin E does not always
differentiate between the types of patterns shown in Figure 1B and
C. We therefore assumed that a fraction of cells staining strongly
for cyclin E throughout S-phase is a more dangerous phenotype
than having a fraction of cells staining for cyclin E only in early S-
phase, and then set out to visually compare the staining patterns
within each matched patient pair. Two independent investigators
(FE and AZ) could in a double-blind set-up correctly tell which
Table 1 The matching of the included patients, and the resulting cyclin E and cyclin A staining fractions
Cyc E+ of cyc A+
Outcome Smoker HRT Parity Age Stage Size Grade Aver (%) Low (%) High (%) E+ (%) A+ (%)
Survivor Y N 2 49 Ib 1 2 16 13 17 16 25
Deceased N N 3 50 Ib 2 2 20 18 20 17 18
Survivor Y N 3 49 Ib 4 1 17 15 20 16 22
Deceased Y N 4 48 Ib 5 2 26 26 27 16 39
Survivor Y N 3 35 Ib 1 2 15 11 23 5 3
Deceased N N 3 37 Ib 2 3 27 24 31 16 22
Survivor N N 0 42 Ib 3 2 19 18 20 16 25
Deceased N N 1 42 Ib 4 2 26 24 28 11 21
Survivor Y N 1 31 Ib 2 1 12 5 16 18 30
Deceased N N 2 32 Ib 4 1 18 17 18 21 29
Survivor ? N 1 48 Ib 2 1 16 14 17 8 14
Deceased Y Y 3 49 Ib 4 2 25 24 26 15 32
Survivor Y N 3 41 Ib 2 1 26 25 27 11 30
Deceased N N 4 36 Ib 0 1 12 6 23 22 25
Survivor Y N 0 33 Ib 5 1 29 24 36 7 10
Deceased N N 2 30 IIa 3 1 15 7 23 23 19
Survivor N N 2 35 IIa 7 1 18 16 20 19 26
Deceased Y N 2 36 IIa 4 1 23 23 23 18 13
Survivor Y N 3 54 IIa 2 1 30 29 31 17 13
Deceased ? N 3 57 IIa 2 2 14 11 16 20 23
Survivor N N 1 40 Ib 4 1 20 10 32 13 18
Deceased ? N 5 39 Ib 2 2 27 26 28 9 29
Survivor N N 3 42 Ib 1 2 23 16 29 16 30
Deceased N N 2 38 Ib 1 1 34 29 37 13 36
Survivor Y N 3 30 IIa 4 2 19 12 25 13 35
Deceased Y N 1 38 IIa 4 1 29 26 31 15 29
Survivor ? N 4 57 Ib 2 2 4 2 6 31 36
Deceased Y N 2 60 Ib 5 1 31 25 37 14 26
Survivor N Y 3 55 Ib 2 2 25 12 32 14 25
Deceased N Y 0 51 Ib 4 1 26 20 33 15 20
Survivor N N 2 52 Ib 3 1 17 3 24 27 21
Deceased N N 2 54 Ib 4 1 26 21 29 21 23
Survivor Y Y 2 49 Ib 2 2 13 7 20 13 27
Deceased Y N 0 44 Ib 5 1 20 14 23 16 30
Survivor N N 3 36 Ib 2 1 16 11 19 18 32
Deceased N N 2 39 Ib 3 1 25 25 27 16 21
Survivors 2.2 43.2 2.9 18.6 15.4 23.4
Deceased 2.3 43.3 3.2 23.6 16.5 25.3
HRT¼hormone replacement therapy. The column ‘Cyc E+ of cyc A+’ exhibits the fraction of cells staining for cyclin A (i.e., cells in S- or G2-phase) that were found to stain for
cyclin E. ‘Aver’ contains the average throughout the tumour. During image acquisition, two to five different areas containing roughly 1000 cells each were photographed from
each tumour. When each area was analysed individually, there were some variations between the areas within the same tumour, hence ‘low’ and ‘high’ shows the fractions in the
areas with the least and the highest cyclin E staining out of the studied areas in the tumour. The data show that intratumoural variations in the expression pattern of cyclin E exist,
indicating that tumours develop different clones with varying degrees or varying mechanisms of disturbed cell cycle control. ‘Size’ contains the tumour size measured in
centimetres, and ‘grade’ shows the tumour differentiation grade, 1¼poorly differentiated, 3¼moderately, 5¼well differentiated. The columns A+ and E+ exhibit the fraction of
all cells staining positive for cyclin A and cyclin E, respectively.
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spatient died in 15/16 out of the 18 pairs (Po0.002, Po0.0001)
simply by visually evaluating plots as in Figure 1. The pairs in
which the tumours exhibited similar percentages of cyclin E
staining cells among the cyclin A-positive cells were the pairs that
were the hardest to separate also by visual evaluation, indicating
that the two methods of evaluation yielded similar results.
Predictive value of only cyclin E or only cyclin A staining
Table 1 lists the fraction of cells staining for cyclin E out of all cells
in each tumour. The percentages ranged from 12 to 34%, and in
only 10 out of the 18 pairs did the deceased patient have a higher
fraction of cells staining for cyclin E than the survivor. The
percentage of cells staining for cyclin A out of all cells ranged from
3 to 39%, and in nine out of the 18 pairs did the deceased patient
exhibit a higher fraction (i.e., higher proliferation) than the
survivor. Therefore, we conclude that in our small study, we could
not find any significant difference in the overall expression of
cyclin E between deceased and survivors. Neither could we find a
significant difference in proliferation, measured as fraction of cells
staining for cyclin A, between the deceased and the survivors.
However, the averages for cyclin E and cyclin A staining were
slightly higher in the deceased patients (Table 1, bottom right),
which indicates a tendency that would probably become significant
in a larger study.
Cyclin E could not be detected in M-phase cells
As the presence of cyclin A-positive cells with high cyclin E levels
was found to be clinically relevant, we also wanted to investigate
the cyclin E levels during mitosis. By visual identification of cells
containing condensed chromosomes, the cells in M-phase could be
investigated in more than 50 squamous carcinomas, as well as in
17 ACs, from the uterine cervix. Not one single M-phase nucleus
containing cyclin E could be found throughout all of the studied
tumours. An example of a tumour with a highly aberrant cyclin E
expression pattern is shown in Figure 2A. Virtually all cells
staining for cyclin A also stains for cyclin E, but the M-phase cells
do not. This indicates that although the tumour cells commonly
fail to degrade cyclin E during S and/or G2, they succeed to do so
before M-phase entry.
The development of cyclin E aberrations in consecutive
progressing lesions
We also attempted to study when in the transformation process
that cyclin E begins to appear in parallel with cyclin A. Tissue
samples containing everything between normal or inflamed
epithelium to invasive squamous carcinoma, including cervical
intraepithelial neoplasia (CIN) and carcinoma in situ lesions, from
11 different patients were studied. None of the studied biopsies
containing normal or inflamed epithelium exhibited any areas
where cyclin A-positive cells contained cyclin E at significant
levels. One of the invasive carcinomas exhibited gravely aberrant
expression pattern. However, the highest expression of cyclin E
among cyclin A-positive cells in an invasive lesion was 24%,
similar to the expression in the CIN2 lesion biopsied 55 months
prior exhibited (25%).
Cyclin E expression pattern in ACs of the uterine cervix
In order to investigate the frequency of heterochronic cyclin E
expression in ACs of the uterine cervix, we stained and evaluated
tumour tissue from 17 patients. Similar to the studied SCCs, the
ACs exhibited highly varying levels of cyclin E in cells expressing
cyclin A. Also in ACs not infected by HPV did we find highly
aberrant cyclin E expression patterns, indicating that HPV
infection is not a prerequisite for parallel cyclin E and cyclin A
expression. In the tumours from deceased patients, the percentages
were 15, 25, 31, and 37%, rendering an average of 27%, which was
not significantly different from the 24% average among the
survivors (P¼0.52).
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Figure 1 At least three different patterns of cyclin E and cyclin A expression over the cell cycle could be distinguished. All three plates (A–C) come from
cervical carcinoma lesions, although plate A is very similar to the pattern seen in normal or inflamed cervical tissue. Each dot in the plots represents the cyclin
A and cyclin E measurements from one cell nucleus in the image shown underneath. Cells with higher cyclin A content are cells in S- or G2-phase. Cells with
low cyclin A and cyclin E contents are cells in early G1, whereas the cells with a low cyclin A content and a high cyclin E content are either senescent cellso r
cells in late G1. In the images, DAPI-stained nuclei are blue, cyclin A is green, and cyclin E is red. In plate A, all cells containing cyclin E are senescent or in late
G1. In plate B, some cells in early S-phase retain an intermediate amount of cyclin E before degrading it in G2 (G2 cells have the highest cyclin A content). In
the tumour shown in plate C, cyclin E is primarily present in S- and G2-cells, and is expressed throughout S-phase.
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sDISCUSSION
In recent years, the expression pattern of cyclin E has acquired
increased interest as deregulated expression of cyclin E potentially
could result in genomic instability, and thereby tumour progres-
sion. We used carefully selected tumour biopsies, immunofluor-
escence staining, digital image acquisition, and image analysis in
order to study the clinical implications of a parallel expression of
cyclin E and cyclin A, most likely caused by a heterochronic cyclin
E expression (the expression of cyclin E during S and G2). We
found that cyclin E was commonly expressed in parallel with cyclin
A, both in squamous carcinomas and in ACs of the uterine cervix,
and that the degree of the aberration was related to patient
survival. We could not detect a single tumour cell in M-phase
containing cyclin E, which indicates that cyclin E is consistently
degraded before M-phase entry in tumours of the uterine cervix.
The study of the cyclin E expression pattern in vivo puts high
demands on the methodological approach. We choose to rely on
the expression of cyclin A to determinate the position in the cell
cycle of each investigated cell, as we have previously shown that
cyclin A reaches detectable levels at the G1/S border, and continues
to accumulate until M-phase both in normal and transformed cells
(Erlandsson et al, 2000). M-phase cells were identified solely based
on morphology. The main disadvantage to using cyclin A staining
as a marker of cell cycle position is that image analysis techniques
must be utilised in order to reach an acceptable level of reliability,
which makes the evaluation process tedious and time consuming.
Therefore, we had to design our study for maximum efficiency.
Progress in the near future may automate parts of the process,
such as image acquisition, preprocessing, segmentation, and data
extraction. Consistent tissue-handling routines, and more robust
antibodies would also speed up and simplify the evaluation of the
cyclin E expression over the cell cycle.
Our main result is that parallel expression of cyclin E and cyclin
A is clinically significant, and may be a marker for poor prognosis.
Others have previously seen an association between cyclin E
overexpression and survival, either using Western blotting (Porter
et al, 1997; Datta et al, 2000; Keyomarsi et al, 2002), histochemistry
(Porter et al, 1997; Datta et al, 2000; Keyomarsi et al, 2002), or flow
cytometry (Darzynkiewicz et al, 1996; Nielsen et al, 1999). Our
study is fundamentally different from those previous studies, as we
neither studied the total amount of cyclin E in the tissue nor just
the number of cells staining for cyclin E. Instead, we focused on
how cyclin E is expressed in relation to cyclin A expression, which
is likely to be related to how cyclin E is expressed over the cell
cycle. Our results fall well in line with those previous studies, as
cyclin E expression during a larger part of the cell cycle often will
lead to an increased total amount of cyclin E in the tissue, as well
as an increased fraction of cells staining for cyclin E. However, in
the search for the link between cyclin E expression and clinical
outcome, it is crucial to know whether it is the heterochronic
expression of cyclin E, rather than the amount of cyclin E in the
tissue, that causes the genetic instability.
There are several potential explanations to why a high cyclin E
level in parallel with cyclin A expression may result in a more
dangerous tumour. It has previously been suggested that hetero-
chronic expression of cyclin E can cause chromosomal aberrations
in cells transfected with the cyclin E1 gene CCNE (Spruck et al,
1999). Furthermore, the accumulation of cyclin E in Skp2 /  mice
was associated with an increase in centrosome aberrations and
polyploidy (Nakayama et al, 2000). Therefore, heterochronic
expression of cyclin E has been proposed to cause aneuploidy,
which is known to be associated with poor outcome in human
cancers. However, in squamous carcinoma of the uterine cervix,
virtually all tumours are aneuploid. Our findings that a parallel
expression of cyclin E and cyclin A is related to poor outcome is
therefore likely to be caused by some other mechanism or process
than just the precipitation of aneuploidy by cyclin E expression
throughout the cell cycle.
Recent in vitro studies have shown that high cyclin E levels
throughout the cell cycle may result in the construction of
defective pre-replication complexes in early G1 (Ekholm-Reed
DAPI Cyclin A Cyclin E
A
B
Figure 2 Cyclin E was degraded before mitosis in all investigated cervical carcinoma lesions. Plate A shows an example of a tumour with four M-phase
cells (marked by arrows). Neither of them stain positive for cyclin E. Plate B shows cells transfected with CCNE, the cyclin E gene, which express high levels
of cyclin E throughout the cell cycle. Also, M-phase cells transfected with cyclin E exhibit a clear cyclin E staining, which excludes the possibility of a
methodological error.
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set al, 2004a). This mechanism does, however, seem unlikely to play
a big part in cervical carcinomas, as we show that M-phase cells,
and subsequently also cells in early G1, do not contain any cyclin
E. In more general terms, our findings that the levels of cyclin E
rarely or never are completely free of cell cycle control in vivo in
cervical carcinomas raise some questions regarding the applic-
ability of transfection studies in vitro in which cell cycle-regulated
proteins are ubiquitously expressed in order to mimic the situation
in tumours. However, the generality of our M-phase data is
questioned by a study proving that cyclin E can, at least in rare
cases, appear in M-phase cells in human endometrial tumours
(Ekholm-Reed et al, 2004b).
There are two more possible explanations to our findings, which
we have failed to control for. If cyclin A begins to accumulate
prematurely, for instance, owing to oncogenic activation in the
signalling cascades, then the cyclin E peak which usually occurs in
late G1 might instead occur during an S-phase triggered
prematurely by cyclin A. Premature S-phase entry could then
cause a defective DNA replication, and the parallel cyclin E and
cyclin A levels would merely be a symptom, not the cause, of the
cell cycle aberration. Finally, our data even paradoxically suggest
that the lack of high cyclin E levels during G1 (see Figure 1, plates
A, B, and C) could be the cause of the more malignant phenotype
of the cervical carcinomas, as the expression pattern in Figure 1,
plate C generally was associated with worse outcome than the
patterns shown in Figure 1, plates A and B.
The data we present herein indicates that the expression pattern
of cyclin E compared to the cyclin A expression pattern over the
cell cycle is an important factor for outcome of patients with
cervical carcinomas. Today, proliferation markers such as cyclin A,
Ki-67, or proliferating cell nuclear antigen are commonly used in
routine investigations, but in this paper we show that the cyclin E
expression pattern may be a better predictor of outcome. Larger
cohort studies will naturally have to be performed before the
introduction of the method in routine clinical praxis. Furthermore,
future mechanistic studies revealing the true nature of the
connection between cyclin E overexpression and patient survival
are highly desirable, as they have the potential to uncover novel
therapeutic targets as well as sharpen the currently used rather
blunt diagnostic and prognostic tools.
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